Clovis Oncology (CLVS) shares collapse 42% after its CO-101 treatment failed to prolong the...

|About: Clovis Oncology (CLVS)|By:, SA News Editor

Clovis Oncology (CLVS) shares collapse 42% after its CO-101 treatment failed to prolong the survival of patients with pancreatic cancer vs gemcitabine in a phase III study. Clovis is now ending the development of the drug pending further evaluation of the trial data.